Search results
Showing 31 to 44 of 44 results for eczema
This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get better without antibiotics. Withholding antibiotics rarely leads to complications.
Discontinued Reference number: GID-NG10289
Evidence-based recommendations on reslizumab (Cinqaero) for treating severe eosinophilic asthma in adults.
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Discontinued Reference number: GID-TA10764
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued Reference number: GID-TA10596
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
Discontinued Reference number: GID-TA10597
This guideline covers identifying and managing otitis media with effusion (OME), also known as ‘glue ear’, in children younger than 12 years. It aims to improve hearing and quality of life in children with OME.
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)
Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.
The appeal panel is drawn from a group of people approved by the Secretary of State for Health and Social Care to hear appeals.
Our centralised approach to prioritising guidance topics ensures that we produce guidance that is relevant, timely, accessible, and has demonstrable impact.